Navigation Links
European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent

SUNNYVALE, Calif., May 18 /PRNewswire/ -- Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1).  The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.  


"Molecular Devices is extremely pleased that the European Patent Office will uphold our planar patch-clamp patent," said Mark Verheyden, President of Molecular Devices, Inc. "This planar patch clamp patent is one of several that are of strategic importance to our automated electrophysiology business. The innovation that went into these patents enables the development of next generation automated electrophysiology platforms, such as the IonWorks Barracuda™ High-Speed Automated Patch Clamp System."

The ruling recognizes Molecular Devices novel application of using an electric field to position and seal cells for electrophysiological measurement on a planar substrate. This capability has revolutionized the way pharmaceutical and biotechnology companies screen new chemical entities against ion channel targets implicated in diseases such as, hypertension, cardiac arrhythmias, cystic fibrosis, immune disorders, and pathological pain.

The European Patent was originally filed with the EPO on 28 July 1998 and granted on 05 September 2001. Opposition of the patent was filed by a single company on the grounds that particular prior art deprived the patents of novelty or inventiveness. On 14 April 2010, the EPO found the patent to be novel and inventive with an amended set of method claims.    

About Molecular Devices: At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at  

Molecular Devices®, the Molecular Devices logo, IonWorks®, IonWorks Barracuda™, and all other trademarks are the property of Molecular Devices, Inc.

SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... , Nov. 30, 2015 Varian Medical Systems (NYSE: ... an educational partnership with Apollo Hospitals Group, the largest hospital chain ... will help train radiation technologists in the country. The MoU was ... Apollo Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... At Grand Dental ... and convenient setting. , When you have dental problems, you need to turn to ... can effectively diagnose and treat your needs, a friendly dentist who counsels you on ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... in general dentistry out of Glen Ridge, NJ. He has both advanced ... achieve optimal mastication. He is also an expert in cosmetic dentistry. He ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a new study by UPMC and KingMed Diagnostics researchers. ... three years found that consultation with UPMC pathologists resulted in significantly altered treatment ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting of ... December 1, 2015, to coincide with World AIDS Day. The multi-media project will be ... the AIDS epidemic as he was dying of the disease. , A collaborative effort ...
Breaking Medicine News(10 mins):